Background Crizotinib has been approved for the treatment of non-small-cell lung cancer
(NSCLC) with ROS proto-oncogene 1 (ROS1) gene fusion. This drug has also been granted …

Six-transmembrane epithelial antigen of prostate-1 (STEAP1) is a relatively newly identified
gene target from prostate cancer, breast cancer, and gastric cancer. However, functions of …

Anaplastic lymphoma kinase (ALK) fusion events account for~ 3–7% genetic alterations in
patients with non-small cell lung cancer (NSCLC). In this study, we identified the ALK fusion …

ABSTRACT EML4–ALK is an oncogenic fusion present in∼ 5% of non-small cell lung
cancers. However, alternative breakpoints in the EML4 gene lead to distinct variants of …

Pancreatic cancer is the seventh leading cause of cancer death among men and women
worldwide, with. 430,000 deaths in 2018. 1 Despite advances in surgical techniques …

BACKGROUND Oncocytic carcinoma of the thyroid is a rare disease, characterized by a
poor prognosis and low response rate to radioiodine therapy. Crizotinib is a specific …

Background Little is known about real‐world treatment and outcomes of patients with
anaplastic lymphoma kinase‐positive (ALK+) advanced non‐small cell lung cancer …

Background HER2 mutation is found in 1%–2% of lung cancer patients. Studies comparing
chemotherapy to HER2‐TKIs are limited. This study aimed to investigate the molecular and …

Background EML4-ALK is a distinct molecular entity that is highly sensitive to ALK tyrosine
kinase inhibitors (TKIs). Immune checkpoint inhibitors (ICIs) have not proved efficacy in ALK …

Background The aim of this study was to evaluate the potential of liquid biopsy for prediction
of the efficacy of epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) …